Expanded profiling of Remdesivir as a broad-spectrum antiviral and low potential for interaction with other medications in vitro.


Journal

Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288

Informations de publication

Date de publication:
23 02 2023
Historique:
received: 16 11 2022
accepted: 06 02 2023
entrez: 23 2 2023
pubmed: 24 2 2023
medline: 3 3 2023
Statut: epublish

Résumé

Remdesivir (GS-5734; VEKLURY) is a single diastereomer monophosphoramidate prodrug of an adenosine analog (GS-441524). Remdesivir is taken up by target cells and metabolized in multiple steps to form the active nucleoside triphosphate (GS-443902), which acts as a potent inhibitor of viral RNA-dependent RNA polymerases. Remdesivir and GS-441524 have antiviral activity against multiple RNA viruses. Here, we expand the evaluation of remdesivir's antiviral activity to members of the families Flaviviridae, Picornaviridae, Filoviridae, Orthomyxoviridae, and Hepadnaviridae. Using cell-based assays, we show that remdesivir can inhibit infection of flaviviruses (such as dengue 1-4, West Nile, yellow fever, Zika viruses), picornaviruses (such as enterovirus and rhinovirus), and filoviruses (such as various Ebola, Marburg, and Sudan virus isolates, including novel geographic isolates), but is ineffective or is significantly less effective against orthomyxoviruses (influenza A and B viruses), or hepadnaviruses B, D, and E. In addition, remdesivir shows no antagonistic effect when combined with favipiravir, another broadly acting antiviral nucleoside analog, and has minimal interaction with a panel of concomitant medications. Our data further support remdesivir as a broad-spectrum antiviral agent that has the potential to address multiple unmet medical needs, including those related to antiviral pandemic preparedness.

Identifiants

pubmed: 36823196
doi: 10.1038/s41598-023-29517-9
pii: 10.1038/s41598-023-29517-9
pmc: PMC9950143
doi:

Substances chimiques

remdesivir 3QKI37EEHE
Antiviral Agents 0
Adenosine Monophosphate 415SHH325A
Alanine OF5P57N2ZX

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

3131

Informations de copyright

© 2023. The Author(s).

Références

PLoS Negl Trop Dis. 2017 Feb 23;11(2):e0005389
pubmed: 28231247
J Gen Virol. 2001 Jun;82(Pt 6):1283-1290
pubmed: 11369871
Clin Pharmacol Ther. 2020 Aug;108(2):242-247
pubmed: 32246834
PLoS One. 2017 Jan 17;12(1):e0169648
pubmed: 28095508
Sci Rep. 2017 Mar 06;7:43395
pubmed: 28262699
J Med Chem. 2017 Mar 9;60(5):1648-1661
pubmed: 28124907
mBio. 2018 Mar 6;9(2):
pubmed: 29511076
J Infect Dis. 2020 Nov 9;222(11):1894-1901
pubmed: 32479636
Nat Commun. 2019 May 22;10(1):2265
pubmed: 31118422
Nat Commun. 2020 Oct 15;11(1):5214
pubmed: 33060595
Sci Transl Med. 2019 May 29;11(494):
pubmed: 31142680
Front Microbiol. 2020 Jun 12;11:1105
pubmed: 32595613
PLoS Negl Trop Dis. 2014 May 01;8(5):e2804
pubmed: 24786461
Sci Rep. 2021 Sep 30;11(1):19458
pubmed: 34593911
Front Pharmacol. 2021 Aug 13;12:706901
pubmed: 34483914
J Biol Chem. 2022 Feb;298(2):101529
pubmed: 34953856
Sci Transl Med. 2017 Jun 28;9(396):
pubmed: 28659436
Sci Rep. 2019 Jul 10;9(1):10021
pubmed: 31292511
Antiviral Res. 2019 Sep;169:104541
pubmed: 31233808
Curr Opin Virol. 2016 Jun;18:126-34
pubmed: 27344481
Viruses. 2021 Oct 06;13(10):
pubmed: 34696439
PLoS Negl Trop Dis. 2022 Mar 8;16(3):e0010220
pubmed: 35259154
J Med Chem. 2021 Apr 22;64(8):5001-5017
pubmed: 33835812
Antiviral Res. 2019 Nov;171:104592
pubmed: 31473342
PLoS Negl Trop Dis. 2016 May 10;10(5):e0004695
pubmed: 27163257
Future Med Chem. 2021 Jan;13(1):5-8
pubmed: 33225723
Clin Pharmacokinet. 2016 Aug;55(8):907-23
pubmed: 26798032
Expert Rev Anti Infect Ther. 2015 Apr;13(4):417-25
pubmed: 25695406
Sci Transl Med. 2020 Apr 29;12(541):
pubmed: 32253226
Pharmacol Rev. 1989 Jun;41(2):93-141
pubmed: 2692037
Gastroenterology. 2014 Apr;146(4):1070-83
pubmed: 24361467
Nature. 2016 Mar 17;531(7594):381-5
pubmed: 26934220
Nat Commun. 2020 Jan 10;11(1):222
pubmed: 31924756
Antimicrob Agents Chemother. 2010 Aug;54(8):3099-106
pubmed: 20516274
Cell Host Microbe. 2016 Jun 8;19(6):891-900
pubmed: 27198478
Bioorg Med Chem Lett. 2012 Apr 15;22(8):2705-7
pubmed: 22446091
Antiviral Res. 2013 May;98(2):242-7
pubmed: 23470860
Emerg Microbes Infect. 2020 Dec;9(1):2256-2265
pubmed: 32981479
Proc Soc Exp Biol Med. 1966 Jan;121(1):190-3
pubmed: 4285768
Cell Rep. 2021 Jul 27;36(4):109450
pubmed: 34289384
Nucleic Acids Res. 2022 May 17;:
pubmed: 35580060
Virology. 1990 Jun;176(2):643-7
pubmed: 2345967
Nat Commun. 2021 Nov 5;12(1):6415
pubmed: 34741049
Cell Rep. 2020 Jul 21;32(3):107940
pubmed: 32668216
Sci Transl Med. 2022 May 4;14(643):eabm3410
pubmed: 35315683
Antimicrob Agents Chemother. 2010 Dec;54(12):5269-80
pubmed: 20837762
Molecules. 2022 Jun 14;27(12):
pubmed: 35744940
Emerg Infect Dis. 1995 Jan-Mar;1(1):1-6
pubmed: 8903147
Antiviral Res. 2009 Jun;82(3):95-102
pubmed: 19428599
Drugs. 2020 Sep;80(13):1355-1363
pubmed: 32870481

Auteurs

Sheli R Radoshitzky (SR)

The Geneva Foundation, United States Army Medical Research Institute of Infectious Diseases (USAMRIID), Fort Detrick, Frederick, MD, USA.
Division of Antivirals, Office of Infectious Diseases, Center for Drug Evaluation and Research, Food and Drug Administration, Silver Spring, MD, USA.

Patrick Iversen (P)

The Geneva Foundation, United States Army Medical Research Institute of Infectious Diseases (USAMRIID), Fort Detrick, Frederick, MD, USA.

Xianghan Lu (X)

Gilead Sciences, Inc, 333 Lakeside Drive, Foster City, CA, USA.

Jing Zou (J)

Department of Biochemistry & Molecular Biology, Institute for Drug Discovery, Sealy Center for Structural Biology & Molecular Biophysics, University of Texas Medical Branch, Galveston, TX, USA.

Suzanne J F Kaptein (SJF)

KU Leuven Department of Microbiology, Immunology and Transplantation, Laboratory of Virology and Chemotherapy, Rega Institute for Medical Research, B-3000, Leuven, Belgium.
Global Virus Network, GVN, Baltimore, USA.

Kelly S Stuthman (KS)

The Geneva Foundation, United States Army Medical Research Institute of Infectious Diseases (USAMRIID), Fort Detrick, Frederick, MD, USA.

Sean A Van Tongeren (SA)

The Geneva Foundation, United States Army Medical Research Institute of Infectious Diseases (USAMRIID), Fort Detrick, Frederick, MD, USA.

Jesse Steffens (J)

The Geneva Foundation, United States Army Medical Research Institute of Infectious Diseases (USAMRIID), Fort Detrick, Frederick, MD, USA.

Ruoyu Gong (R)

Gilead Sciences, Inc, 333 Lakeside Drive, Foster City, CA, USA.

Hoa Truong (H)

Gilead Sciences, Inc, 333 Lakeside Drive, Foster City, CA, USA.

Annapurna A Sapre (AA)

Gilead Sciences, Inc, 333 Lakeside Drive, Foster City, CA, USA.

Huiling Yang (H)

Gilead Sciences, Inc, 333 Lakeside Drive, Foster City, CA, USA.

Xiaodong Xie (X)

Gilead Sciences, Inc, 333 Lakeside Drive, Foster City, CA, USA.

Jia Jun Chia (JJ)

Gilead Sciences, Inc, 333 Lakeside Drive, Foster City, CA, USA.

Zhijuan J Song (ZJ)

Gilead Sciences, Inc, 333 Lakeside Drive, Foster City, CA, USA.

Stacey M Leventhal (SM)

Gilead Sciences, Inc, 333 Lakeside Drive, Foster City, CA, USA.

Josolyn Chan (J)

Gilead Sciences, Inc, 333 Lakeside Drive, Foster City, CA, USA.

Alex Shornikov (A)

Gilead Sciences, Inc, 333 Lakeside Drive, Foster City, CA, USA.

Xin Zhang (X)

KU Leuven Department of Microbiology, Immunology and Transplantation, Laboratory of Virology and Chemotherapy, Rega Institute for Medical Research, B-3000, Leuven, Belgium.
Global Virus Network, GVN, Baltimore, USA.

David Cowfer (D)

Gilead Sciences, Inc, 333 Lakeside Drive, Foster City, CA, USA.

Helen Yu (H)

Gilead Sciences, Inc, 333 Lakeside Drive, Foster City, CA, USA.

Travis Warren (T)

The Geneva Foundation, United States Army Medical Research Institute of Infectious Diseases (USAMRIID), Fort Detrick, Frederick, MD, USA.
Laulima Government Solutions, LLC., Orlando, FL, USA.

Tomas Cihlar (T)

Gilead Sciences, Inc, 333 Lakeside Drive, Foster City, CA, USA.

Danielle P Porter (DP)

Gilead Sciences, Inc, 333 Lakeside Drive, Foster City, CA, USA.

Johan Neyts (J)

KU Leuven Department of Microbiology, Immunology and Transplantation, Laboratory of Virology and Chemotherapy, Rega Institute for Medical Research, B-3000, Leuven, Belgium.
Global Virus Network, GVN, Baltimore, USA.

Pei-Yong Shi (PY)

Department of Biochemistry & Molecular Biology, Institute for Drug Discovery, Sealy Center for Structural Biology & Molecular Biophysics, University of Texas Medical Branch, Galveston, TX, USA.

Jay Wells (J)

The Geneva Foundation, United States Army Medical Research Institute of Infectious Diseases (USAMRIID), Fort Detrick, Frederick, MD, USA.

John P Bilello (JP)

Gilead Sciences, Inc, 333 Lakeside Drive, Foster City, CA, USA.

Joy Y Feng (JY)

Gilead Sciences, Inc, 333 Lakeside Drive, Foster City, CA, USA. joy.feng@gilead.com.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH